Supplementary Materials

The PDF file includes:

  • Fig. S1. Establishment of a high-throughput chemical drug screen.
  • Fig. S2. Drug response at 5 and 21% O2.
  • Fig. S3. Human bone marrow–derived control cells in the counter screen.
  • Fig. S4. KIF11 mRNA expression and gene dependency.
  • Fig. S5. Biochemical properties of ARRY-520 and AR649.
  • Fig. S6. KSP abundance in neuroblastoma cells.
  • Fig. S7. KSP inhibition causes neuroblastoma cell cycle arrest.
  • Fig. S8. ARRY-520 causes neuroblastoma cell death.
  • Fig. S9. Anti-neuroblastoma effects of KSP inhibitors SB-743921 and ispinesib.
  • Fig. S10. Immunohistochemistry of tumors after AR649 treatment of mice.
  • Fig. S11. Characteristics of AR649-treated LU-NB-3 PDX model.
  • Fig. S12. Characteristics of ARRY-520–treated LU-NB-1 orthotopic PDX model.
  • Fig. S13. Characteristics of ARRY-520–treated LU-NB-2 orthotopic PDX model.
  • Fig. S14. Characteristics of low-dose ARRY-520 treatment in the LU-NB-3 PDX model.
  • Table S1. KIF11 gene dependency analysis of neuroblastoma cell lines.
  • Table S2. ARRY-520 sensitivity in neuroblastoma cell lines.
  • Legends for data files S1 to S4
  • References (5355)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Original data for figures presenting mean values.
  • Data file S2 (Microsoft Excel format). Complete list of the 525 drugs (the FIMM oncology set) included in the high-throughput screen.
  • Data file S3 (Microsoft Excel format). Complete data from the high-throughput drug screen.
  • Data file S4 (Microsoft Excel format). Complete gene ontology list based on up-regulated genes after ARRY-520 treatment of LU-NB-2 PDX cells.